10/11/2024  5:31:59 PM Chg. +0.79 Volume Bid9:42:23 PM Ask9:42:23 PM Market Capitalization Dividend Y. P/E Ratio
99.44CHF +0.80% 2.19 mill.
Turnover: 217.17 mill.
-Bid Size: 124 -Ask Size: 16 226.16 bill.CHF - -

Business description

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. Novartis products are sold in approximately 155 countries around the world.
 

Management board & Supervisory board

CEO
Vasant Narasimhan, M.D.
Management board
Harry Kirsch, Dr. Klaus Moosmayer, Dr. Steffen Lang, Karen L. Hale, Rob Kowalski, Shreeram Aradhye, Victor Bulto, Aharon (Ronny) Gal, Dr. Fiona H. Marshall, Patrick Horber
Supervisory board
Dr. Joerg Reinhardt, Bridgette Heller, Charles L. Sawyers, M.D., Dr. Charlotte Pamer-Wieser, Dr. Nancy C. Andrews, Elizabeth Doherty, Frans van Houten, Simon Moroney, Ton Buechner, William T. Winters, Daniel Hochstrasser, Ana de Pro Gonzalo, John D. Young, Patrice Bula
 

Company data

Name: Novartis AG
Address: Lichtstrasse 35,CH-4002 Basel
Phone: +41-61-324-1111
Fax: +41-61-324-8001
E-mail: -
Internet: www.novartis.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 86.85%
IPO date: 3/7/1996

Investor relations

Name: Imke Kappes
IR phone: +41 61 324 8269
IR Fax: -
IR e-mail: investor.relations@n...tis.com investor.relations@novartis.com

Company calendar

CW 44 | 10/29/2024 Interim Report 3rd Quarter/9 Months
CW 5 | 1/31/2025 4th Quarter/Annual Report
CW 10 | 3/7/2025 General Shareholder Meeting
 

Main Shareholders

Others
 
91.20%
Emasan AG, Basel
 
3.90%
UBS Fund Management (Switzerland) AG, Basel
 
2.70%
Credit Suisse Funds AG, Zurich
 
2.20%